Please turn JavaScript on

Science Media Centre

Receive updates from Science Media Centre for free, starting right now.

We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.

This way you won't miss any new article from Science Media Centre. Unsubscribe at any time.

Site title: Science Media Centre

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.52 / day

Message History

Two studies published in The Lancet look at a blood test and new brain scan for detecting early biomarkers for Alzheimer’s Disease. 

 

Prof Roslyn Bill, 50th Anniversary Professor of Biotechnology, College of Health & Life Sciences, Aston University, said:

(on brain scan) “Alzheimer’s dise...


Read full story

Last year the UK National Screening Committee (UK NSC) conducted an updated review of evidence for prostate cancer screening to assess whether the balance of benefits versus risks/harms had been tipped in favour of a targeted or population-based national screening programme.

In November the UK NSC announced their draft recommendation was for targeted screening only for...


Read full story

Scientists comment on a final recommendation for a national screening programme for prostate cancer from the UK National Screening Committee (UKNSC).

 

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, said:

“We are pleased to see that individuals with a BRCA2 pathogenic alteration will now b...


Read full story

Journalists came to hear from researchers in the UK who are leading efforts to rapidly develop vaccines and therapeutics for Ebola, specifically for the Bundibugyo virus which is responsible for the current outbreak in the Democratic Republic of the Congo and Uganda.

CEPI were also on the call to discuss the work they’re doing on Ebola and the current outbreak to suppo...


Read full story

Scientists comment on topline results from a phase III clinical trial of the hormone receptor agonist Retatrutide. 

 

Dr Marie Spreckley, Research Programme Manager, University of Cambridge, said:

“Retatrutide is an experimental once-weekly triple hormone receptor agonist that acts on GLP-1, GIP and glucagon receptors. This diff...


Read full story